BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451
BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.
You may also be interested in...
Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals leads to removal of indications for two PD-1/L-1 inhibitors, AstraZeneca’s Imfinzi and Bristol-Myers Squibb’s Opdivo, both of which had failed confirmatory trials.
The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor
Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.